U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661095) titled 'A Study of CRD3874-SI in People With Leukemia' on June 16.
Brief Summary: The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
AML
Refractory Acute Myeloid Leukemia
Intervention:
DRUG: CRD3874-SI
CRD3874-SI is a STING (Stimulator of Interferon Genes) agonist in participants with relapsed and refractory (R/R) acute myeloid leukemia (AML).
Recruitment Status: RECRUITING
Sponsor: Memorial Sloan Kettering Cancer Center
Disclaimer: Curated by HT Syndication....